vs
Side-by-side financial comparison of Axos Financial, Inc. (AX) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($619.8M vs $392.2M, roughly 1.6× Axos Financial, Inc.). Axos Financial, Inc. runs the higher net margin — 31.8% vs -14.8%, a 46.6% gap on every dollar of revenue. Over the past eight quarters, Axos Financial, Inc.'s revenue compounded faster (16.1% CAGR vs -6.6%).
Axos Financial is an American bank holding company based in Las Vegas, Nevada and is the parent of Axos Bank, a direct bank. It also offers registered investment adviser services and an electronic trading platform.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
AX vs QDEL — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $392.2M | $619.8M |
| Net Profit | $124.7M | $-91.8M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | 31.8% | -14.8% |
| Revenue YoY | — | -10.5% |
| Net Profit YoY | 18.5% | — |
| EPS (diluted) | $2.15 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $392.2M | $619.8M | ||
| Q4 25 | $385.1M | — | ||
| Q3 25 | $323.4M | $699.9M | ||
| Q2 25 | $321.4M | $613.9M | ||
| Q1 25 | $308.8M | $692.8M | ||
| Q4 24 | $307.9M | $707.8M | ||
| Q3 24 | $320.7M | $727.1M | ||
| Q2 24 | $290.9M | $637.0M |
| Q1 26 | $124.7M | $-91.8M | ||
| Q4 25 | $128.4M | — | ||
| Q3 25 | $112.4M | $-733.0M | ||
| Q2 25 | $110.7M | $-255.4M | ||
| Q1 25 | $105.2M | $-12.7M | ||
| Q4 24 | $104.7M | $-178.4M | ||
| Q3 24 | $112.3M | $-19.9M | ||
| Q2 24 | $104.9M | $-147.7M |
| Q1 26 | — | — | ||
| Q4 25 | 45.6% | — | ||
| Q3 25 | 46.3% | -100.7% | ||
| Q2 25 | 48.5% | -29.4% | ||
| Q1 25 | 47.9% | 4.7% | ||
| Q4 24 | 48.8% | -14.2% | ||
| Q3 24 | 49.6% | 2.1% | ||
| Q2 24 | 49.6% | -18.4% |
| Q1 26 | 31.8% | -14.8% | ||
| Q4 25 | 33.3% | — | ||
| Q3 25 | 34.7% | -104.7% | ||
| Q2 25 | 34.4% | -41.6% | ||
| Q1 25 | 34.1% | -1.8% | ||
| Q4 24 | 34.0% | -25.2% | ||
| Q3 24 | 35.0% | -2.7% | ||
| Q2 24 | 36.0% | -23.2% |
| Q1 26 | $2.15 | $-1.35 | ||
| Q4 25 | $2.22 | — | ||
| Q3 25 | $1.94 | $-10.78 | ||
| Q2 25 | $1.89 | $-3.77 | ||
| Q1 25 | $1.81 | $-0.19 | ||
| Q4 24 | $1.80 | $-2.54 | ||
| Q3 24 | $1.93 | $-0.30 | ||
| Q2 24 | $1.75 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $140.4M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $3.1B | $1.9B |
| Total Assets | $29.2B | $5.6B |
| Debt / EquityLower = less leverage | — | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $140.4M | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $2.6B | $98.1M | ||
| Q2 25 | $1.9B | $151.7M | ||
| Q1 25 | $2.0B | $127.1M | ||
| Q4 24 | $2.4B | $98.3M | ||
| Q3 24 | $2.6B | $143.7M | ||
| Q2 24 | $2.0B | $107.0M |
| Q1 26 | — | $2.5B | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | $312.7M | $2.1B | ||
| Q1 25 | $377.4M | $2.1B | ||
| Q4 24 | $358.7M | $2.1B | ||
| Q3 24 | $313.5M | $2.2B | ||
| Q2 24 | $325.7M | $2.2B |
| Q1 26 | $3.1B | $1.9B | ||
| Q4 25 | $2.9B | — | ||
| Q3 25 | $2.8B | $2.0B | ||
| Q2 25 | $2.7B | $2.8B | ||
| Q1 25 | $2.6B | $3.0B | ||
| Q4 24 | $2.5B | $3.0B | ||
| Q3 24 | $2.4B | $3.2B | ||
| Q2 24 | $2.3B | $3.2B |
| Q1 26 | $29.2B | $5.6B | ||
| Q4 25 | $28.2B | — | ||
| Q3 25 | $27.4B | $5.7B | ||
| Q2 25 | $24.8B | $6.4B | ||
| Q1 25 | $24.0B | $6.5B | ||
| Q4 24 | $23.7B | $6.4B | ||
| Q3 24 | $23.6B | $6.8B | ||
| Q2 24 | $22.9B | $6.7B |
| Q1 26 | — | 1.33× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | 0.12× | 0.74× | ||
| Q1 25 | 0.14× | 0.70× | ||
| Q4 24 | 0.14× | 0.72× | ||
| Q3 24 | 0.13× | 0.68× | ||
| Q2 24 | 0.14× | 0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AX
| Net Interest Income | $306.3M | 78% |
| Noninterest Income | $86.0M | 22% |
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
